Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CLDXthis companyCelldex Therapeutics, Inc.	$30.98	-6.96×	3.43×	1,204.09×	-6.97×	-99.2%	100.0%	-19160.0%	-17253.3%	-49.1%	-53.9%	-11.8%	0×	0.1×	0×	10.49×	0.0%	2	16.42	2	C
AGENAgenus Inc.	$7.55	-923.53×	-0.34×	0.82×	6.84×	-468.1%	29.6%	-18.0%	0.1%	-0.0%	-34.5%	-170.2%	-1.24×	5.34×	-0.37×	0.41×	0.0%	6	-14.32	2	C+
CMPXCompass Therapeutics, Inc.	$0.80	-12.79×	4.3×	0×	-12.7×	-84.0%	0.0%	0.0%	0.0%	-33.8%	-35.3%	-5.8%	0.05×	0.32×	0×	15.02×	0.0%	3	-0.29	2	C+
IMNMImmunome, Inc.	$19.14	-8.84×	2.96×	270.32×	-5.86×	-62.3%	57.4%	-3084.8%	-3060.0%	-33.5%	-33.5%	-10.7%	0.01×	3.1×	0×	14.69×	0.0%	2	31.88	2	C+
MGNXMacroGenics, Inc.	$2.47	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
NRIXNurix Therapeutics, Inc.	$16.09	-5.54×	2.72×	17.45×	-5.2×	-213.0%	77.5%	-340.2%	-314.9%	-49.1%	-47.3%	-18.0%	0.1×	0.78×	0×	7.02×	0.0%	7	9.1	4	A-
Peer median	—	-8.84×	2.72×	0.82×	-5.2×	-213.0%	57.4%	-48.7%	-49.9%	-33.8%	-34.5%	-18.0%	0.05×	0.78×	0×	7.02×	0.0%	3	-0.29	2	—